FENC NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Fennec Pharmaceuticals Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 9.57 USD
-4.2% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 14.6% above the Trend Line and sits at 69.3% of its 52-week range. The latest completed week returned -4.2%, after a -10.6% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 45 out of 100
Latest Close 9.57 USD 31 Jul 2026
1W Return -4.2% latest completed week
4W Return -10.6% short-term follow-through
12W Return 38.1% quarterly tape
Trend Breadth 46.2% 24 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • The trend backdrop is active with a 10-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 2 reversal markers appear in the recent smart-money tape.
  • Recent volatility is running well above the one-year baseline.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.2% Latest completed week; four-week move -10.6%. Indicator stack 60/61 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 52/100 conviction; expected move 17.1%. News sentiment 50/100 50 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 14.6% above the Trend Line and sits at 69.3% of its 52-week range. The latest completed week returned -4.2%, after a -10.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8912-week average 0.46

12-week confirmation

Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership9/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.89Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -10.6% over four weeks, 38.1% over 12 weeks, and 22.1% over one year. The current trend has remained active for 10 consecutive weeks.

Performance by holding period

1W-4.2%
4W-10.6%
12W38.1%
26W26.1%
52W22.1%
Active trend streak10 weeks
Active weeks in one year24
Trend breadth46.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.74Latest activity-pressure read.
Pressure change-33.0%Four-week change in activity pressure.
Leadership5.07Latest relative-leadership reading.
RS change-61.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength11/100Blend of value, momentum, and quality. Underlying universe rank 90; rank 1 is best.
Value16/100Relative valuation strength. Underlying universe rank 85; rank 1 is best.
Quality11/100Profitability and accounting quality. Underlying universe rank 90; rank 1 is best.
Momentum69/100Medium-term price momentum. Underlying universe rank 32; rank 1 is best.
Growth87/100Revenue and earnings growth. Underlying universe rank 14; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
6.8x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-1.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
92.2%
Gross profit retained from each unit of revenue.
Operating margin
-13.3%
Operating profit retained from revenue.
Free-cash-flow margin
-11.3%
Free cash flow generated from revenue.
Return on invested capital
-30.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
65.0%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
0/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-12.1%
Net share repurchases relative to market value.
Shareholder yield
-12.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
3.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

FENC shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of n/a, expected move of 17.1%, and Sharemaestro trend signal active.

Conviction52/100
Expected move17.1%
Put/call volume
Pressure-89
Speculation6
Volatility90
Trend agreement18
Open options detail
Insider activity16 / 4

16 acquisitions and 4 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment50/100

Weighted news tone is neutral across 50 relevant articles.

8 positive · 36 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move17.1%Nearest-chain priced movement where available.
52-week drawdown-15.4%Distance below the 52-week high.
13-week volatility13.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2612 weeks finished lower.
Best week+40.7%Week of 15 May.
Worst week-19.3%Week of 27 Mar.
Latest week-4.2%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains7
Flat weeks1
Modest losses5
Sharp losses7
Recent vol13.0%13-week weekly-return volatility.
Base vol8.8%52-week weekly-return volatility.
Up/down split27/23Count of positive and negative weeks in the 52-week window.
Average skew6.1% / -5.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape46/100

Trend, activity pressure, participation, and risk combine to a 46/100 tape read.

 Indicator analysis75/100

Latest 12-week confirmation: trend 10/12, activity pressure 11/12, relative leadership 9/12.

Activity pressure 0.89; 2 reversal markers Factors24/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 88; Small Cap Core rank 89 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options41/100

FENC shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of n/a, expected move of 17.1%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 17.1% Sentiment50/100

Weighted news tone is neutral across 50 relevant articles.

Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks Insiders16 / 4

16 acquisitions and 4 disposals in the latest 180-day insider tape.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20269.57 USD-4.2%8.35 USD7.69 USD0.745.07476.5KOn
24 Jul 20269.99 USD-4.9%8.29 USD7.68 USD0.9510.24645.3KOn
17 Jul 202610.50 USD0.1%8.22 USD7.67 USD1.1913.90963.3KOn
10 Jul 202610.49 USD-2.0%8.13 USD7.65 USD1.139.06750.8KOn
3 Jul 202610.70 USD-2.9%8.03 USD7.64 USD1.1113.02884.6KOn
26 Jun 202611.02 USD21.6%7.93 USD7.63 USD1.0317.262.3MOn
19 Jun 20269.06 USD0.7%7.83 USD7.61 USD0.99-7.871.0MOn
12 Jun 20269.00 USD3.4%7.79 USD7.61 USD1.10-6.381.1MOn
5 Jun 20268.70 USD-12.4%7.75 USD7.62 USD1.22-7.761.3MOn
29 May 20269.93 USD0.0%7.73 USD7.62 USD0.910.021.9MOn
22 May 20269.93 USD1.8%7.67 USD7.61 USD0.332.581.4MOff
15 May 20269.75 USD40.7%7.64 USD7.59 USD-0.201.703.3MOff
8 May 20266.93 USD6.0%7.59 USD7.57 USD-0.71-27.89865.9KOff
1 May 20266.54 USD-4.4%7.65 USD7.58 USD-0.89-28.45615.7KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.